Shanghai Mediumbank Biotechnology Co., LTD. (MediumBank) was established in 2019. It is a high-tech biotechnology enterprise focused on providing integrated solutions for upstream bioprocess. MediumBank has cataloged media products for a variety of cell lines and provides customized services such as media optimization and development (MOD), cell culture processing development, original entrusted manufacture for dry powder and liquid media, cell culture supernatant analysis and detection.
Since its establishment, with professional experience and technical accumulation, MediumBank's products and services have covered CHO cells, HEK293 cells, insect cells, T cells/stem cells, Sp2/0 & NS0 cells, Vero cells and other major cell platforms, the performance of most products and services have reached the international leading level. In 2021, MediumBank's MFG1 production capacity, constructed to GMP standards, officially commenced production, the construction of the MFG2 mass production base continued to make progress. In 2022, the company flawlessly passed the ISO13485 quality system certification, achieving further upgrades in production management and quality systems. In 2023, MediumBank was awarded the title of " specialized, high-end and innovation-driven" completed quality audits by several Chinese listed biopharmaceutical companies, was the first to complete the DMF filing for the dual feed medium (MaxFA/FB), and successfully expanded several products to international markets.
Currently, MediumBank’s clients encompass a wide range of biopharmaceutical companies, including those focused on monoclonal antibodies, fusion proteins, vaccines for animals or humans, IVD, cell and gene therapies, and cultured meat. MediumBank's products and services have been validated by over 600+ biopharmaceutical companies worldwide, widely used in various stages of biopharmaceutical research and development, clinical filings, and commercial production, earning recognition, trust, and support from hundreds of companies in the industry..
Currently, MediumBank Biotech's clients encompass a wide range of biopharmaceutical companies, including those focused on monoclonal antibodies, fusion proteins, vaccines for animals or humans, IVD, cell and gene therapies, and cultured meat. MediumBank's products and services have been validated by over 600+ biopharmaceutical companies worldwide, widely used in various stages of biopharmaceutical research and development, clinical filings, and commercial production, earning recognition, trust, and support from hundreds of companies in the industry.
MediumBank makes bioprocesses simpler and more efficient!
